Abstract
Инфекционные осложнения у пациентов с множественной миеломой, перенесших аутологичную трансплантацию стволовых клеток периферической крови
Highlights
Over recent decades, significant advances were made in treatment of hematological malignancies, which were primarily associated with intensive antitumor therapy and hematopoietic stem cell transplantation (HSCT)
Our results demonstrate that bacterial complications and viral (CMV and Epstein-Barr virus (EBV)) reactivation aggravate the course of primary disease in MM patients over the post-transplant period
Significant advances were made in treatment of hematological malignancies, which were primarily associated with intensive antitumor therapy and hematopoietic stem cell transplantation (HSCT)
Summary
Significant advances were made in treatment of hematological malignancies, which were primarily associated with intensive antitumor therapy and hematopoietic stem cell transplantation (HSCT). Probability of 10-year survival among hematological cancer patients subjected to HSCT is 85%, as shown by the large study performed by Wingard et al [1]. Multiple myeloma accounts for approximately 10% of oncohematological disorders, and 1% of total cancer incidence. The concept of high-dose chemotherapy followed by autologous HSCT was dated back to early 980s and remains the ‘golden standard’ for treating newly diagnosed MM in young and some older patients. The advent of novel agents, such as immunomodulatory drugs, proteasome inhibitors and monoclonal antibodies does not compete with ASCT. The novel approaches supported its central role as the standard of care [2]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
